veriNOS pharmaceuticals GmbH
- Home
- Companies
- veriNOS pharmaceuticals GmbH
- Services
- Neuro-Oncology Services
Neuro-Oncology Services
Ronopterin – treatment to reduce peritumoral brain edema and improve patient outcomes. Adequate pharmacologic control of peritumoral edema in glioblastoma and brain metastases is still insufficient and is limited by side effects in more than 50% of the patients.
Most popular related searches
brain metastases
tumor growth
intracranial pressure
metastasis
depression
intracranial
oncology
brain cancer
Ronopterin offers a potential solution to address the unmet medical need as Ronopterin decreases edema formation by inhibiting the cell damaging effects of radicals and glutamate.
- Mechanistically similar edema formation as in TBI
- synthetic steroids used in routine therapy
- increase iNOS expression and radical formation
- fail to reduce brain edema
- worsen outcome
- tumor growth and brain metastasis formation
- increase glutamate release in brain with decreased glutamate uptake
- Aiming to reduce brain edema and edema-induced increase in intracranial pressure as a superior alternative to steroids and to decrease side effects of steroids
Worldwide approx. 300’000 patients suffer from glioblastoma and approx. 500’000 patients experience brain metastases annually.
Incidences in glioblastoma and brain metastases are projected to increase by 10% within the next 10 years.
Current treatments show insufficient efficacy with high incidence of declining neurocognitive function, personality changes, mood disturbances, depression, reduced quality of life.
In more than 50% of patient’s synthetic steroids fail to reduce peritumoral brain edema which may promote recurrence of aggravated edema formation and tumor growth.
The high economic burden and undermet medical need account for a market potential of 5 bn USD annually by 2030.